Steven M. Fruchtman - Feb 7, 2023 Form 4 Insider Report for Onconova Therapeutics, Inc. (ONTX)

Role
PRESIDENT, CHIEF EXECUTIVE OFF, Director
Signature
/s/ Mark Guerin, Attorney-in-Fact
Stock symbol
ONTX
Transactions as of
Feb 7, 2023
Transactions value $
-$9,489
Form type
4
Date filed
2/8/2023, 05:00 PM
Previous filing
Aug 4, 2022
Next filing
Mar 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONTX Common Stock Options Exercise +21.3K +81.58% 47.5K Feb 7, 2023 Direct F1
transaction ONTX Common Stock Tax liability -$9.49K -6.98K -14.7% $1.36 40.5K Feb 7, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONTX Restricted Stock Units Options Exercise $0 -21.3K -33.33% $0.00 42.6K Feb 7, 2023 Common Stock 21.3K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 On February 7, 2022 the reporting person was granted 63,960 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.